5(s)​ ​hpete

5(S)-Hydroperoxyeicosatetraenoic acid (5(S)-HpETE) is a monohydroperoxy polyunsaturated fatty acid (PUFA) generated by the enzymatic conversion of arachidonic acid via 5-lipoxygenase (5-LO). Subsequently, 5(S)-HpETE undergoes metabolism to form leukotriene A4 (LTA4), which serves as a pivotal intermediate in the synthesis of leukotrienes (LTs).

15(S)-HpETE is a product of arachidonic acid formed in the 15-lipoxygenase pathway and inhibits angiogenesis. 15(S)-HpETE can upregulate the expression of CD31, E-selectin, and gene selectin in cells.

1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PC is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PC is toxic to human umbilical vein endothelial cells (HUVECs) when used at a concentration of 100 μM.

1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PE is a phospholipid with stearic acid at the sn-1 position and 15(S)-HpETE at the sn-2 position, produced by oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE by 15-lipoxygenase (15-LO). At concentrations of 0.6 and 0.9 μM, it increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.

The lipoxins are trihydroxy fatty acids containing a 7,9,11,13-conjugated tetraene. Lipoxin A4 (LXA4) was first described as a metabolite of 15-HpETE and/or 15-HETE when added in vitro to isolated human leukocytes. The material obtained in this manner consists of at least four distinct isomers: 5(S), 6(S); 5(S), 6(R); and the 11-trans and 11-cis isomers of each of these. 6(S)-LXA4 is one of the original four metabolites first identified by Serhan, Nicolaou, and Samuelsson. It was considered to be an artifact by these authors because it lacked the potency of the 5(S),6(R) isomer with respect to contraction of isolated guinea pig lung parenchymal strips. It has not been possible to isolate natural" LXA4 from humans or other mammals in amounts sufficient for determination of absolute stereochemistry. Most authors refer to LXA4 as the 5(S)

15(S)-HETrE is the hydroxy-trienoic acid resulting from 15-lipoxygenation of dihomo-γ-linolenic acid. It inhibits 5-LO in human PMNL with an IC50 value of 4.6 μM. In RBL cells, 15(S)-HETrE also inhibits 5-LO, but is approximately 1/20 as potent as 15(S)-HpETE.

5(R)-HETE is a rare lipoxygenase product of arachidonic acid. Nearly all plant and animal 5-LOs produce 5(S)-HETE, but the presence of a 5(R)-LO and the synthesis of 5(R)-HpETE and 5(R)-HETE have been confirmed in oocytes of the bivalve mollusk, S. solidissima. 5(R)-HETE is more potent than the (S)-enantiomer as a chemotactic agent for human neutrophils.

12(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of platelet or leukocyte 12-lipoxygenase (12-LO) on arachidonic acid. It activates human blood leukocyte 5-LOE. 12(S)-HpETE is the mediator of many biological functions, including induction of c-fos and c-jun, activation of AP-1, and endothelium-dependent vasoconstriction. It mediates the inhibitory synaptic response to FMRF-amide in Aplysia sensory neurons and inhibits Ca2+/calmodulin-dependent protein kinase II from rat brain cortex.